Clinical insights into the cross-link between mood disorders and type 2 diabetes : A review of longitudinal studies and Mendelian randomisation analyses
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
Mood disorders and type 2 diabetes mellitus (T2DM) are prevalent conditions that often co-occur. We reviewed the available evidence from longitudinal and Mendelian randomisation (MR) studies on the relationship between major depressive disorder (MDD), bipolar disorder and T2DM. The clinical implications of this comorbidity on the course of either condition and the impact of antidepressants, mood stabilisers, and antidiabetic drugs were examined. Consistent evidence indicates a bidirectional association between mood disorders and T2DM. T2DM leads to more severe depression, whereas depression is associated with more complications and higher mortality in T2DM. MR studies demonstrated a causal effect of MDD on T2DM in Europeans, while a suggestive causal association in the opposite direction was found in East Asians. Antidepressants, but not lithium, were associated with a higher T2DM risk in the long-term, but confounders cannot be excluded. Some oral antidiabetics, such as pioglitazone and liraglutide, may be effective on depressive and cognitive symptoms. Studies in multi-ethnic populations, with a more careful assessment of confounders and appropriate power, would be important.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:152 |
|---|---|
| Enthalten in: |
Neuroscience and biobehavioral reviews - 152(2023) vom: 25. Sept., Seite 105298 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Possidente, Chiara [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.08.2023 Date Revised 09.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.neubiorev.2023.105298 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358923603 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358923603 | ||
| 003 | DE-627 | ||
| 005 | 20231226075756.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.neubiorev.2023.105298 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM358923603 | ||
| 035 | |a (NLM)37391112 | ||
| 035 | |a (PII)S0149-7634(23)00267-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Possidente, Chiara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical insights into the cross-link between mood disorders and type 2 diabetes |b A review of longitudinal studies and Mendelian randomisation analyses |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.08.2023 | ||
| 500 | |a Date Revised 09.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Mood disorders and type 2 diabetes mellitus (T2DM) are prevalent conditions that often co-occur. We reviewed the available evidence from longitudinal and Mendelian randomisation (MR) studies on the relationship between major depressive disorder (MDD), bipolar disorder and T2DM. The clinical implications of this comorbidity on the course of either condition and the impact of antidepressants, mood stabilisers, and antidiabetic drugs were examined. Consistent evidence indicates a bidirectional association between mood disorders and T2DM. T2DM leads to more severe depression, whereas depression is associated with more complications and higher mortality in T2DM. MR studies demonstrated a causal effect of MDD on T2DM in Europeans, while a suggestive causal association in the opposite direction was found in East Asians. Antidepressants, but not lithium, were associated with a higher T2DM risk in the long-term, but confounders cannot be excluded. Some oral antidiabetics, such as pioglitazone and liraglutide, may be effective on depressive and cognitive symptoms. Studies in multi-ethnic populations, with a more careful assessment of confounders and appropriate power, would be important | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Depression | |
| 650 | 4 | |a Glucagon-like peptide-1 (GLP-1) receptor agonists | |
| 650 | 4 | |a Glycaemic control | |
| 650 | 4 | |a Insulin resistance | |
| 650 | 4 | |a Metformin | |
| 650 | 4 | |a Mood stabilisers | |
| 650 | 4 | |a Non-insulin-dependent diabetes | |
| 650 | 4 | |a Oral hypoglycaemics | |
| 650 | 4 | |a Pioglitazone | |
| 650 | 4 | |a Selective serotonin reuptake inhibitors | |
| 650 | 4 | |a Thiazolidinediones | |
| 650 | 4 | |a Treatment resistance | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Pioglitazone |2 NLM | |
| 650 | 7 | |a X4OV71U42S |2 NLM | |
| 700 | 1 | |a Fanelli, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Serretti, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Fabbri, Chiara |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuroscience and biobehavioral reviews |d 1982 |g 152(2023) vom: 25. Sept., Seite 105298 |w (DE-627)NLM000456977 |x 1873-7528 |7 nnns |
| 773 | 1 | 8 | |g volume:152 |g year:2023 |g day:25 |g month:09 |g pages:105298 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.neubiorev.2023.105298 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 152 |j 2023 |b 25 |c 09 |h 105298 | ||